Filtered By:
Condition: Hypertension
Procedure: Transplants

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 198 results found since Jan 2013.

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Independent risk factors for an increased incidence of thromboembolism after lung transplantation
ConclusionsThe incidence of TE after LTX is high, especially in lung transplant recipients with a BMI  >  25 and an age >  55 years as well as cardiovascular risk factors closely associated with the metabolic syndrome. As these patients comprise a growing recipient fraction, intensified research should focus on the risks and benefits of regular screening or a prolonged TE prophylaxis in these patients.Trial registration number DKRS: 00021501.
Source: Journal of Thrombosis and Thrombolysis - December 10, 2022 Category: Hematology Source Type: research

Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment
AbstractPurpose of ReviewTesticular cancer (TC) is the leading cancer in men between 18 and 39  years of age. Current treatment involves tumor resection followed by surveillance and/or one or more lines of cisplatin-based chemotherapy (CBCT) and/or bone marrow transplant (BMT). Ten years after treatment, CBCT has been associated with significant atherosclerotic cardiovascular disease (CVD) i ncluding myocardial infarction (MI), stroke, and heightened rates of hypertension, dyslipidemia, diabetes mellitus, and metabolic syndrome (MetS). Additionally, low testosterone levels and hypogonadism contribute to MetS and may furth...
Source: Current Oncology Reports - March 3, 2023 Category: Cancer & Oncology Source Type: research

Clonal Hematopoiesis and the Heart: a Toxic Relationship
AbstractPurpose of ReviewClonal hematopoiesis (CH) refers to the expansion of hematopoietic stem cell clones and their cellular progeny due to somatic mutations, mosaic chromosomal alterations (mCAs), or copy number variants which naturally accumulate with age. CH has been linked to increased risk of blood cancers, but CH has also been linked to adverse cardiovascular outcomes.Recent FindingsA combination of clinical outcome studies and mouse models have offered strong evidence that CH mutations either correlate with or cause atherosclerosis, diabetes mellitus, chronic kidney disease, heart failure, pulmonary hypertensi...
Source: Current Oncology Reports - March 15, 2023 Category: Cancer & Oncology Source Type: research

Cardiac transplant and exercise cardiac rehabilitation
AbstractCardiac transplantation is the final therapeutic option for patients with end-stage heart failure. Most patients experience a favorable functional ability post-transplant. However, episodes of acute rejection, and multiple comorbidities such as hypertension, diabetes mellitus, chronic kidney disease and cardiac allograft vasculopathy are common. The number of transplants has increased steadily over the past two decades with 3,817 operations performed in the United States in 2021. Patients have abnormal exercise physiologic responses related to surgical cardiac denervation, diastolic dysfunction, and the legacy of r...
Source: Heart Failure Reviews - April 4, 2023 Category: Cardiology Source Type: research

Cytomegalovirus and cardiovascular disease: a hypothetical role for viral G protein-coupled receptors in hypertension
Am J Hypertens. 2023 May 6:hpad045. doi: 10.1093/ajh/hpad045. Online ahead of print.ABSTRACTCytomegalovirus (CMV) is a member of the β- herpesviruses and is ubiquitous, infecting 50-99% of the human population depending on ethnic and socioeconomic conditions. CMV establishes lifelong, latent infections in their host. Spontaneous reactivation of CMV is usually asymptomatic, but reactivation events in immunocompromised or immunosuppressed individuals can lead to severe morbidity and mortality. Moreover, herpesvirus infections have been associated with several cardiovascular and post-transplant diseases (stroke, atherosclero...
Source: Atherosclerosis - May 6, 2023 Category: Cardiology Authors: Gisele F Bomfim Fernanda Priviero Emma Poole Rita C Tostes John H Sinclair Dimitrios Stamou Mark J Uline Mark R Wills R Clinton Webb Source Type: research

Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation
ConclusionsElevated plasma levels of ADM may be a marker of pressure/volume overload in HF patients with PH, as well as long-term prognosis after HT. In line with previous studies, our findings additionally confirm that ADM may be a marker of venous congestion in HF. Further studies are encouraged to establish a deeper understanding of the properties of ADM and its relationship with HF and PH, in order to potentially facilitate clinical management of HF and associated PH.
Source: ESC Heart Failure - May 29, 2023 Category: Cardiology Authors: Abdulla Ahmed, Kriss Kania, Hebba Abdul Rahim, Salaheldin Ahmed, G öran Rådegran Tags: Original Article Source Type: research